Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

The ASUNCTIS trial evaluated asunercept's safety and efficacy in COVID-19, showing trends toward faster recovery despite not ...

Before propensity matching, mothers of tetracycline-exposed infants were more often in the youngest and oldest age strata and ...

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) ...

Together with its safety endpoints, the RCT achieved statistical significance ... Once the six-month results analysis is completed, LivaNova will submit the OSPREY clinical data to the U.S. Food and ...

Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of evaluable patients achieved stable diseaseColon ...

Two separate phase 3 trials show that semaglutide improved fatty liver disease ... the SELECT phase 3 cardiovascular outcomes trial, an exploratory post hoc analysis showed semaglutide 2.4 mg reduced ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Conclusions This study provides strong preclinical rationale and safety in patients with cirrhosis to allow ... data acquisition and analysis; clinical trial lead; paper organisation, drafting and ...

is a 5-HT2C receptor agonist in Phase 2 trials. BMB-101 is indicated for drug-resistant epilepsy and other rare epileptic disorders. Phase 1 results were promising, with a favorable safety profile ...